Please ensure Javascript is enabled for purposes of website accessibility

bluebird bio Stock Soars on Unprecedented Blood Cancer Study Results

By George Budwell - Dec 11, 2017 at 9:15AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's experimental CAR-T therapy with Celgene Corp. may be a game changer for multiple myeloma.

What happened

Shares of the clinical-stage biotech bluebird bio (BLUE 6.41%) rose by as much as 23.9% in pre-market trading today. The catalyst? The company reported that its CAR-T candidate, bb2121, produced "unprecedented responses" in patients with advanced forms of the deadly blood cancer known as multiple myeloma in a small, early-stage dose-escalation study.

Bluebird is co-developing bb2121 with Celgene Corp. (CELG) as part of their broader gene therapy in oncology partnership. As a result, Celgene's shares are also up by 3.7% in pre-market in response to the duo's presentation at the American Society of Hematology Annual Meeting over the weekend, where these data were originally unveiled.

Human blood viewed under a microscope.

Image source: Getty Images.

So what

The jaw-dropping part of the presentation that's driving bluebird and Celgene's shares higher this morning is that a surreal 94% (17/18) of patients in the study exhibited objective responses to the experimental cell-based therapy. Moreover, the two companies reported that at least seven patients were complete responders at the last cut-off date.

In addition to bb2121's promising efficacy profile, the therapy's safety data were among the cleanest ever reported for a CAR-T therapy thus far. So while this study was indeed small, bluebird and Celgene may have a game changer on their hands for advanced multiple myeloma. 

Now what

Not surprisingly, bluebird and Celgene plan on rapidly advancing bb2121 into a larger, pivotal-stage trial as soon as possible. These results, after all, are essentially a first for a multiple myeloma treatment of any kind. These two companies could therefore become the third group to bring a CAR-T therapy to market all within a few months' time. And if this line holds, bluebird is probably going to be a highly sought after buyout candidate in 2018, based on the immense demand for these novel cell therapies right now.    

George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bluebird Bio and Celgene. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Celgene Corporation Stock Quote
Celgene Corporation
bluebird bio, Inc. Stock Quote
bluebird bio, Inc.
$6.31 (6.41%) $0.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.